Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors
Shots:
- The first patient has been dosed in a P-I CIBI323A101 study evaluating IBI323 (anti-LAG-3/PD-L1 bispecific Ab) in patients with advanced solid tumors. The trial is being conducted in China
- The purpose of the P-I dose-escalation and expansion study is to evaluate the safety- tolerability- optimal dosage- and preliminary efficacy of IBI323 in patients with advanced malignant tumors whose cancer progressed on SoC treatment
- The preclinical studies showed that IBI323 effectively blocks both the PD-1/PD-L1 and LAG-3 pathways and enhance the T lymphocyte activation compared with the combination of anti-PD-L1 and anti-LAG mAb
Ref: PR Newswire | Image: Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com